Nationwide, outbreak.info estimates that BA.2.86’s cumulative prevalence — which represents a ratio of sequences containing BA.2.86 to all sequences collected in the U.S. since the subvariant was first detected on July 29 — is less than 0.5 percent.
The subvariant made headlines in August because of its large number of mutations, however emerging research suggests the strain may not be as transmissible or immune-evasive as experts initially thought.
Below is a breakdown of BA.2.86 prevalence by state, based on data from outbreak.info. As COVID-19 sequencing is not a random sample of mutations, the data represents outbreak.info’s best estimates of the subvariant’s prevalence, as opposed to true prevalence.
Note: Becker’s calculated each state’s estimated cumulative BA.2 presence using sequencing data from outbreak.info. Figures are rounded to the nearest hundredth.
|
State |
BA.2.86 positive samples |
Total sequences sampled |
Estimated cumulative prevalence (%) |
|
Pennsylvania |
1 |
166 |
.60 |
|
Michigan |
1 |
230 |
.43 |
|
Ohio |
1 |
297 |
.34 |
|
Washington |
1 |
532 |
.19 |
|
Virginia |
1 |
541 |
.18 |
|
Colorado |
1 |
750 |
.13 |
|
Texas |
1 |
2,815 |
.04 |
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
